A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Latest Information Update: 10 Mar 2025
Price :
$35 *
At a glance
- Drugs Faricimab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms ELEVATUM
- Sponsors Genentech
- 07 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2025 Planned End Date changed from 31 Jan 2027 to 28 Feb 2027.
- 17 Feb 2025 Planned primary completion date changed from 31 Jan 2027 to 28 Feb 2027.